Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 4,279 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 4,279 shares of Kymera Therapeutics stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $81.58, for a total value of $349,080.82. Following the completion of the transaction, the chief operating officer directly owned 44,018 shares in the company, valued at $3,590,988.44. This represents a 8.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $81.70 on Thursday. The firm has a market capitalization of $6.72 billion, a P/E ratio of -22.89 and a beta of 2.06. Kymera Therapeutics, Inc. has a 1-year low of $28.33 and a 1-year high of $103.00. The business’s 50-day simple moving average is $83.28 and its 200-day simple moving average is $79.14.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the prior year, the business earned ($0.82) earnings per share. The company’s revenue was up 55.5% compared to the same quarter last year. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -3.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. BTIG Research decreased their target price on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. UBS Group upped their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Piper Sandler upped their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.10.

Institutional Trading of Kymera Therapeutics

Several large investors have recently modified their holdings of KYMR. Baker BROS. Advisors LP grew its stake in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP acquired a new stake in shares of Kymera Therapeutics during the third quarter valued at about $47,563,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.